GlassScriptPhysician profile
Tanneisha S Barlow
NPI 1558340190
$12,944.51
in general payments reported to CMS, 2019-2025
48 companies · $1,125 in 2025
The $1,125 reported for 2025 was more than what 91% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $581 · 2020: $315 · 2021: $7,556 · 2022: $1,129 · 2023: $1,256 · 2024: $983 · 2025: $1,125.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,247 · Education: $117.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,246.91 |
| Education | $116.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $6,797.28 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $695.27 | 2019-2025 | |
| Pfizer INC. | $556.17 | 2019-2025 | |
| Astellas Pharma US INC | $517.96 | 2020-2025 | Veozah, Myrbetriq |
| Mayne Pharma Commercial LLC | $438.47 | 2022-2025 | |
| Abbvie INC. | $426.38 | 2019-2023 | Lo Loestrin Fe, Orilissa, Ubrelvy |
| Evofem Biosciences, INC. | $285.80 | 2021-2025 | Phexxi, Solosec, Phexx |
| Aspira Women'S Health INC | $234.39 | 2021-2024 | Ova1 |
| Therapeuticsmd, INC. | $190.85 | 2019-2022 | |
| Daiichi Sankyo INC. | $189.85 | 2019-2021 | |
| Organon LLC | $188.66 | 2022-2025 | Nexplanon, Jada System |
| Sumitomo Pharma America, INC. | $169.67 | 2023-2025 | Myfembree, Gemtesa |
| Biogen, INC. | $157.35 | 2024-2025 | Zurzuvae |
| Exeltis, USA INC. | $156.12 | 2020-2025 | Slynd |
| Avion Pharmaceuticals | $137.90 | 2019-2022 |
Show all 46 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sage Therapeutics, LLC | $137.28 | 2021-2023 | |
| Coopersurgical, INC. | $136.63 | 2019-2025 | Summit Doppler, Endosee, Paragard T 380a |
| Amgen INC. | $124.73 | 2019-2024 | Evenity, Prolia |
| Astellas Pharma Global Development | $124.61 | 2023-2025 | Veozah |
| Shield Therapeutics INC | $115.79 | 2022-2024 | Accrufer |
| Channel Medsystems, INC. | $101.88 | 2023-2024 | |
| Alydia Health | $91.49 | 2021 | |
| Myriad Women'S Health, INC. | $90.12 | 2023 | |
| Agile Therapeutics, INC. | $81.87 | 2023-2024 | Twirla |
| Baxter Healthcare | $72.83 | 2021-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $63.35 | 2022 | |
| Hologic Sales and Service, LLC | $54.30 | 2024-2025 | Acessa Provu System, Aptima, Novasure |
| Ethicon US, LLC | $52.97 | 2019 | |
| Myovant Sciences INC. | $52.18 | 2021-2022 | |
| Millicent US INC | $48.81 | 2021-2024 | |
| Duchesnay USA Incorporated | $43.90 | 2019 | |
| Lupin INC. | $40.66 | 2021 | |
| Novo Nordisk INC | $40.15 | 2024-2025 | Wegovy |
| Amag Pharmaceuticals, INC. | $36.67 | 2019-2020 | |
| Meditrina | $36.66 | 2022 | |
| Scynexis, INC. | $34.58 | 2022 | |
| Vertical Pharmaceuticals, LLC | $33.15 | 2019 | |
| Exact Sciences Corporation | $30.49 | 2023-2025 | Cologuard Collection Kit |
| Mylan Pharmaceuticals INC. | $29.88 | 2019-2021 | |
| Roche Diagnostics Corporation | $24.97 | 2019 | |
| Dexcom, INC. | $23.53 | 2025 | Dexcom G6 Transmitter |
| Medtronic, INC. | $18.77 | 2022 | |
| Lsi Solutions INC | $16.04 | 2024 | Fornisee |
| Bausch Health US, LLC | $15.30 | 2020 | |
| Glaxosmithkline, LLC. | $14.83 | 2020 | |
| Urovant Sciences INC | $13.97 | 2021 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$5.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tanneisha Barlow listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.